(Q37846092)

24 August 2017

1 reference

title

Antibiotic dosing in critically ill patients with acute kidney injury (English)

1 reference

24 August 2017

2

1 reference

24 August 2017

Rachel F Eyler

1

1 reference

PubMed ID

21343897

24 August 2017

Medscape

series ordinal

3

1 reference

PubMed ID

21343897

24 August 2017

language of work or name

English

0 references

publication date

22 February 2011

1 reference

Nature Reviews Nephrology

24 August 2017

1 reference

24 August 2017

7

1 reference

24 August 2017

4

1 reference

24 August 2017

226-235

1 reference

https://scigraph.springernature.com/pub.10.1038/nrneph.2011.12

24 August 2017

0 references

cites work

Principles of antibacterial dosing in continuous renal replacement therapy

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2011.12

A systematic review of antibiotic dosing regimens for septic patients receiving continuous renal replacement therapy: do current studies supply sufficient data?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2011.12

Pharmacokinetic changes in critical illness

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2011.12

The increased intestinal absorption rate is responsible for the reduced hepatic first-pass extraction of propranolol in rats with cisplatin-induced renal dysfunction

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2011.12

Effect of enteral feeding with ensure on oral bioavailabilities of ofloxacin and ciprofloxacin

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2011.12

Pharmacokinetic issues for antibiotics in the critically ill patient

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2011.12

Using population pharmacokinetics to determine gentamicin dosing during extended daily diafiltration in critically ill patients with acute kidney injury

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2011.12

Gentamicin volume of distribution in critically ill septic patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2011.12

Antimicrobial dosing considerations in obese adult patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2011.12

Adjustment of dosing of antimicrobial agents for bodyweight in adults.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2011.12

The importance of antibiotic pharmacokinetics in critical illness

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2011.12

Drug protein binding in chronic renal failure: Evaluation of nine drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2011.12

Pharmacodynamics of tigecycline against phenotypically diverse Staphylococcus aureus isolates in a murine thigh model

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2011.12

Epinephrine impairs splanchnic perfusion in septic shock.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2011.12

Clinical review: Drug metabolism and nonrenal clearance in acute kidney injury

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2011.12

Pharmacokinetics and dosing regimen of meropenem in critically ill patients receiving continuous venovenous hemofiltration.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2011.12

Pharmacokinetic considerations for antimicrobial therapy in patients receiving renal replacement therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2011.12

Effects of renal failure on drug transport and metabolism

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2011.12

The multispecific organic anion transporter family: properties and pharmacological significance

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2011.12

Fluconazole dosing in continuous veno-venous haemofiltration (CVVHF): need for a high daily dose of 800 mg.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2011.12

Drug dosing in continuous renal replacement therapy: general rules

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2011.12

Determinants of vancomycin clearance by continuous venovenous hemofiltration and continuous venovenous hemodialysis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2011.12

Drug dosing during continuous renal replacement therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2011.12

Removal of linezolid by conventional intermittent hemodialysis, sustained low-efficiency dialysis, or continuous venovenous hemofiltration in patients with acute renal failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2011.12

Effect of drug concentration on adsorption of levofloxacin by polyacrylonitrile haemofilters.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2011.12

Clearance of vancomycin during high-volume haemofiltration: impact of pre-dilution

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2011.12

Dose determinants in continuous renal replacement therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2011.12

Daptomycin exposure and the probability of elevations in the creatine phosphokinase level: data from a randomized trial of patients with bacteremia and endocarditis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2011.12

Daptomycin pharmacokinetics in critically ill patients receiving continuous venovenous hemodialysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2011.12

Pharmacodynamics and dosing of aminoglycosides

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2011.12

Clinical and bacteriological efficacy, and practical aspects of amikacin given once daily for severe infections

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2011.12

A prospective randomized study comparing once- versus twice-daily amikacin dosing in critically ill adult and paediatric patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2011.12

Dosing of daptomycin in intensive care unit patients with acute kidney injury undergoing extended dialysis--a pharmacokinetic study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2011.12

Comparing outcomes of meropenem administration strategies based on pharmacokinetic and pharmacodynamic principles: a qualitative systematic review.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2011.12

Pharmacokinetics of meropenem during intermittent and continuous intravenous application in patients treated by continuous renal replacement therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2011.12

Continuous infusion of ceftazidime in critically ill patients undergoing continuous venovenous haemodiafiltration: pharmacokinetic evaluation and dose recommendation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2011.12

Therapeutic drug monitoring of beta-lactams in critically ill patients: proof of concept

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2011.12

Principles of antibacterial dosing in continuous renal replacement therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2011.12

Drug dosage in patients during continuous renal replacement therapy. Pharmacokinetic and therapeutic considerations

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2011.12

Pharmacokinetics of ciprofloxacin in ICU patients on continuous veno-venous haemodiafiltration

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2011.12

Safety and pharmacokinetics of multiple 750-milligram doses of intravenous levofloxacin in healthy volunteers

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2011.12

Pharmacokinetics of levofloxacin and ciprofloxacin during continuous renal replacement therapy in critically ill patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2011.12

Pharmacokinetics of levofloxacin during continuous venovenous hemodiafiltration and continuous venovenous hemofiltration in critically ill patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2011.12

Multiple-dose pharmacokinetics of amikacin and ceftazidime in critically ill patients with septic multiple-organ failure during intermittent hemofiltration

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2011.12

Pharmacokinetics and tolerability of daptomycin at doses up to 12 milligrams per kilogram of body weight once daily in healthy volunteers

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2011.12

Evaluation by monte carlo simulation of the pharmacokinetics of two doses of meropenem administered intermittently or as a continuous infusion in healthy volunteers.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2011.12

Vancomycin pharmacokinetics in normal and morbidly obese subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2011.12

Comparison of steady-state pharmacokinetics of two dosage regimens of vancomycin in normal volunteers

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2011.12

Pharmacokinetics and serum bactericidal activity of vancomycin alone and in combination with ceftazidime in healthy volunteers

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2011.12

Pharmacokinetics and total elimination of meropenem and vancomycin in intensive care unit patients undergoing extended daily dialysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2011.12

Vancomycin pharmacokinetics in critically ill patients receiving continuous venovenous haemodiafiltration

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2011.12

Antibiotic dosing in critically ill adult patients receiving continuous renal replacement therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2011.12

Antimicrobial dosing concepts and recommendations for critically ill adult patients receiving continuous renal replacement therapy or intermittent hemodialysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2011.12

Antimicrobial Resistance: Pharmacokinetics‐Pharmacodynamics of Antimicrobial Therapy: It’s Not Just for Mice Anymore

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2011.12

Pharmacokinetics of piperacillin and tazobactam in critically ill patients with renal failure, treated with continuous veno-venous hemofiltration (CVVH)

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2011.12

Acute Renal Failure in Critically Ill Patients A Multinational, Multicenter Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2011.12

Speed of onset of adaptive mucosal hypoplasia and hypofunction in the intestine of parenterally fed rats

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2011.12

Decreased in vitro fluoroquinolone concentrations after admixture with an enteral feeding formulation

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2011.12

Short report: the absorption of fluconazole and itraconazole under conditions of low intragastric acidity

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2011.12

AKI: fluid overload and mortality

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2011.12

Nephrology consultation in acute renal failure: does timing matter?

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2011.12

Factors affecting gentamicin pharmacokinetics in septic patients

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2011.12

Comparison of imipenem pharmacokinetics in patients with acute or chronic renal failure treated with continuous hemofiltration

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2011.12

Pharmacokinetics of meropenem in intensive care unit patients receiving continuous veno-venous hemofiltration or hemodiafiltration

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2011.12

Vancomycin pharmacokinetics in acute renal failure: preservation of nonrenal clearance

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2011.12

Which reliable pharmacodynamic breakpoint should be advised for ciprofloxacin monotherapy in the hospital setting? A TDM-based retrospective perspective

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2011.12

Proinflammatory cytokines cause down-regulation of renal chloride entry pathways during sepsis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2011.12

Discrepancies between observed and predicted continuous venovenous hemofiltration removal of antimicrobial agents in critically ill patients and the effects on dosing

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2011.12

Continuous renal replacement therapy: A worldwide practice survey

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2011.12

A comparison of molecular clearance rates during continuous hemofiltration and hemodialysis with a novel volumetric continuous renal replacement system

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2011.12

Operational characteristics of continuous renal replacement modalities used for critically ill patients with acute kidney injury.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2011.12

Vancomycin elimination during high-flux hemodialysis: kinetic model and comparison of four membranes

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2011.12

Gentamicin clearance during hemodialysis: a comparison of high-efficiency cuprammonium rayon and conventional cellulose ester hemodialyzers

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2011.12

Vancomycin mass transfer characteristics of high-flux cellulosic dialysers

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2011.12

Higher renal replacement therapy dose delivery influences on drug therapy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2011.12

Rational dosing of antimicrobial agents: pharmacokinetic and pharmacodynamic strategies

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2011.12

Daptomycin clearance during modeled continuous renal replacement therapy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2011.12

Challenges in developing evidence-based drug dosing guidelines for adults and children receiving renal replacement therapy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2011.12

Pharmacokinetics of ciprofloxacin after oral and intravenous administration in healthy volunteers

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2011.12

Pharmacokinetic and clinical studies with amikacin, a new aminoglycoside antibiotic

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2011.12

Pharmacokinetics of meropenem compared to imipenem-cilastatin in young, healthy males

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2011.12

Serum bactericidal activities and comparative pharmacokinetics of meropenem and imipenem-cilastatin.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2011.12

Pharmacokinetics of meropenem in critically ill patients with acute renal failure treated by continuous hemodiafiltration.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2011.12

Removal of piperacillin in critically ill patients undergoing continuous venovenous hemofiltration

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2011.12

Gut dysfunction in critically ill patients: a review of the literature.

31 March 2020

1 reference

12 December 2020

1 reference

12 December 2020

Pharmacokinetic profile of levofloxacin following once-daily 500-milligram oral or intravenous doses

1 reference

12 December 2020

Drug Removal during Continuous Hemofiltration or Hemodialysis

1 reference

12 December 2020

Drug administration in critically ill patients with acute renal failure.

1 reference

12 December 2020

Variable disposition of ciprofloxacin in critically ill patients undergoing continuous arteriovenous hemodiafiltration

1 reference

12 December 2020

Creatinine space as a measure of total body water in anuric subjects, estimated after single injection and haemodialysis

1 reference

12 December 2020

Pharmacokinetics and pharmacodynamics of two multiple-dose piperacillin-tazobactam regimens

1 reference

12 December 2020

CRRT efficiency and efficacy in relation to solute size.

1 reference

12 December 2020

The effect of adsorption, filter material and point of dilution on antibiotic elimination by haemofiltration an in vitro study of levofloxacin

1 reference

12 December 2020

Identifiers

DOI

10.1038/NRNEPH.2011.12

1 reference

24 August 2017

1 reference

PubMed ID

21343897